Quantcast

Latest biopharmaceutical Stories

2014-03-24 08:28:11

MONROVIA, Calif., March 24, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, today announced that Bassil Dahiyat, Ph.D., Chief Executive Officer, will present at the 21st Annual BioCentury Future Leaders in the Biotech Industry Conference on Friday, March 28, 2014 at 9:30 a.m. EDT at the Millennium Broadway Hotel...

2014-03-20 23:31:05

MedVax Technologies, Inc., a biopharmaceutical company developing and commercializing cancer vaccine immunotherapies, announced today that Robert Brooks, Chief Executive Officer, will be presenting a company overview at the 6th Annual Biotech Showcase investor and partnering conference. Miami, FL (PRWEB) March 20, 2014 MedVax Technologies, Inc., a biopharmaceutical company developing and commercializing cancer vaccine immunotherapies, announced today that Robert Brooks, Chief Executive...

2014-03-20 16:26:50

All amounts are in US dollars QUEBEC CITY, March 20, 2014 /PRNewswire/ - Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZ) (the "Company"), a specialty biopharmaceutical company engaged in developing novel treatments in oncology and endocrinology, today reported financial and operating results as at and for the fourth quarter and the year ended December 31, 2013. Revenues for the year ended December 31, 2013 were $6.2 million compared to $2.1 million for the same period in...

2014-03-18 16:25:29

JUPITER, Fla., March 18, 2014 /PRNewswire/ -- Dyadic International, Inc. ("Dyadic") (OTCQX: DYAI), a global biotechnology company focused on the discovery, development, manufacture and sale of enzymes and other proteins for the bioenergy, bio-based chemicals, biopharmaceutical, food and feed industries, announced today details regarding its new project, "OPTIBIOCAT - Optimized esterase biocatalysts for cost-effective industrial production", an EU-funded project aimed at developing...

2014-03-18 08:32:43

-- ABRAXANE plus gemcitabine approved by the TGA for the first-line treatment of metastatic pancreatic cancer MELBOURNE, Australia, March 18, 2014 /PRNewswire/ -- Australian biopharmaceutical company Specialised Therapeutics Australia (STA) is pleased to announce that ABRAXANE(®) (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in now approved by the Therapeutic Goods Administration (TGA) for the first-line treatment of metastatic pancreatic cancer. The TGA approved...

2014-03-16 16:20:46

CAMBRIDGE, England, March 16, 2014 /PRNewswire/ -- Kymab, a monoclonal antibody biopharmaceutical company founded on research from the Wellcome Trust Sanger Institute, announced today the publication in Nature Biotechnology of a paper describing its breakthrough therapeutic antibody discovery technology, Kymouse(TM) (http://dx.doi.org). Scientists at Kymab have engineered a mouse with the full set of genes encoding the human antibody repertoire, calling this...

2014-03-14 12:28:10

GHENT, Belgium, March 14, 2014 /PRNewswire/ -- ActoGeniX NV, creator of ActoBiotics(TM), announced today that Bernard Coulie, Chief Executive Officer, will present a company overview at the 21(st )Annual Future Leaders in the Biotech Industry Conference at 1:30pm ET on Friday, March 28, 2014, at the Millennium Broadway Hotel in New York City. A live webcast of the presentation will be available at the following link: https://www.webcaster4.com/Webcast/Page/392/3742 and on the...

2014-03-13 08:28:48

MONROVIA, Calif., March 13, 2014 /PRNewswire/ -- Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of autoimmune diseases, asthma and allergic diseases, and cancer, announced that it will release fourth quarter and full year 2013 financial results after market close on Wednesday, March 19, 2014. Xencor management will host a webcast and conference call the same day at 4:30 p.m. EDT (1:30 p.m. PDT) to...

2014-03-11 08:29:53

Funding to support clinical development of treatments for rare cholestatic liver diseases and nonalcoholic steatohepatitis SAN DIEGO, March 11, 2014 /PRNewswire/ -- Lumena Pharmaceuticals (Lumena), a biopharmaceutical company focused on the development and commercialization of novel products for rare cholestatic liver diseases and serious metabolic disorders, today announced that it has secured $45 million in Series B financing. New Enterprise Associates (NEA) led the financing,...

2014-03-10 16:30:46

LONDON, March 10, 2014 /PRNewswire/ -- Reportbuyer.com just published a new market research report:Microfluidic Technologies: Biopharmaceutical and Healthcare Applications 2013-2023Report DetailsMicrofluidics - how to find trends, opportunities and revenue prospectsDo you want to assess the potential of microfluidic technologies? Visiongain's new report gives you revenue predictions there from 2013, helping you stay ahead. You find financial data, trends, opportunities, and...


Word of the Day
mundungus
  • A stinking tobacco.
  • Offal; waste animal product; organic matter unfit for consumption.
This word comes from the Spanish 'mondongo,' tripe, entrails.